The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Am J Psychiatry 162:2379-2381, December 2005
doi: 10.1176/appi.ajp.162.12.2379
© 2005 American Psychiatric Association
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
* Citation Map
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by Mathew, S. J.
* Articles by Gorman, J. M.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Mathew, S. J.
* Articles by Gorman, J. M.
Related Collections
* Anxiety Disorders (General)
* Other Somatic Therapy

Brief Report

Open-Label Trial of Riluzole in Generalized Anxiety Disorder

Sanjay J. Mathew, M.D., Jonathan M. Amiel, B.S., Jeremy D. Coplan, M.D., Heidi A. Fitterling, B.A., Harold A. Sackeim, Ph.D., and Jack M. Gorman, M.D.

OBJECTIVE: There is a need to identify novel pharmacotherapies for anxiety disorders. The authors examined the safety and efficacy of riluzole, an antiglutamatergic agent, in adult outpatients with generalized anxiety disorder. METHOD: In an 8-week, open-label, fixed-dose study, 18 medically healthy patients with DSM-IV generalized anxiety disorder received treatment with riluzole (100 mg/day) following a 2-week drug-free period. The primary efficacy measure was the Hamilton Anxiety Rating Scale (HAM-A) score at endpoint. RESULTS: Twelve of the 15 patients who completed the trial responded positively to riluzole. At 8 weeks, eight of the 15 patients had HAM-A score indicating remission of their anxiety. The median time to response was 2.5 weeks. CONCLUSIONS: Riluzole appears to be an effective, well-tolerated, and rapidly acting anxiolytic medication for some patients with generalized anxiety disorder. Larger, placebo-controlled studies are indicated.




This article has been cited by other articles:


Home page
FocusHome page
M. H. Pollack, M. W. Otto, P. P. Roy-Byrne, J. D. Coplan, B. O. Rothbaum, N. M. Simon, and J. M. Gorman
Novel Treatment Approaches for Refractory Anxiety Disorders
Focus, September 1, 2008; 6(4): 486 - 495.
[Abstract] [Full Text] [PDF]




Get information about faster international access.

Privacy Policy

Copyright © 2005 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org